<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725228</url>
  </required_header>
  <id_info>
    <org_study_id>tccRenato2018</org_study_id>
    <nct_id>NCT03725228</nct_id>
  </id_info>
  <brief_title>Lidocaine Compared to Magnesium Sulfate to Prolong Spinal Anesthesia: Non-inferiority Randomized Clinical Trial</brief_title>
  <official_title>Lidocaine Compared to Magnesium Sulfate to Prolong Spinal Anesthesia: Non-inferiority Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brasilia University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brasilia University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of continuous infusion of lidocaine or continuous infusion
      of magnesium sufate in the duration of spinal anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both lidocaine and magnesium sulfate have been shown to prolong spinal anesthesia.

      The number of studies using magnesium sulfate to improve spinal anesthesia is greater than
      the number of studies using lidocaine, and methodology varies significantly between studies.

      Adverse effects of lidocaine are different from magnesium sulfate's. Lidocaine has a wider
      therapeutic interval with fewer side effects, including: Drowsiness, Feeling Anxious, Feeling
      Cold, Nervous, Numbness And Tingling, Signs And Symptoms At Injection Site, Twitching.

      Magnesium sulfate's side effects include: heart disturbances, breathing difficulties, poor
      reflexes, confusion, weakness, flushing (warmth, redness, or tingly feeling), sweating,
      lowered blood pressure, feeling like you might pass out, anxiety, cold feeling, extreme
      drowsiness, muscle tightness or contraction, or headache.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitive block duration</measure>
    <time_frame>9 hours</time_frame>
    <description>Thermal and pinprick level lowering to S2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor block duration</measure>
    <time_frame>9 hours</time_frame>
    <description>Time to Bromage return to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two levels regression</measure>
    <time_frame>9 hours</time_frame>
    <description>Time from maximal thermal (cold) sensitive block level to lower two levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at postanesthesia care unit</measure>
    <time_frame>1-3 hours</time_frame>
    <description>Maximum pain (0-10 verbal scale) during PACU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Anesthesia</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Magnesium Sulfate 15mg/kg/h</description>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine 1,5mg/kg/h</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Will receive spinal anesthesia for TURP por Histerectomy

        Exclusion Criteria:

          -  Protocol violation;

          -  Severe adverse events;

          -  Change to general anesthesia or addition of epidural anesthesia;

          -  Complete or partial spinal block failure;

          -  Mental status alteration (agitation, confusion, loss of conciousness).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universit√°rio de Brasilia</name>
      <address>
        <city>Brasilia</city>
        <state>Distrito Federal</state>
        <zip>70000000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brasilia University Hospital</investigator_affiliation>
    <investigator_full_name>Gabriel Magalhaes Nunes Guimaraes</investigator_full_name>
    <investigator_title>Head of Anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share de-identified IPD in Mendeley Data after study completion</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Analystic code will be published in RPUBS</ipd_time_frame>
    <ipd_access_criteria>Open Access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

